These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31452381)

  • 21. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.
    Verna EC; Saxena V; Burton JR; O'Leary JG; Dodge JL; Stravitz RT; Levitsky J; Trotter JF; Everson GT; Brown RS; Terrault NA;
    Transplantation; 2015 Aug; 99(8):1644-51. PubMed ID: 25715116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.
    Su F; Beste LA; Green PK; Berry K; Ioannou GN
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):686-693. PubMed ID: 28195877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals.
    Gentene AJ; Bell AM; Pence A; Thomas K; Jakubecz C; Stacy E; Woolf B; Guido MR; Mueller EW; Sherman KE
    Ann Pharmacother; 2021 May; 55(5):565-574. PubMed ID: 33016095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response.
    Fernandes FF; Piedade J; Guimaraes L; Nunes EP; Chaves U; Goldenzon RV; Cardoso SW; Duarte J; Grinsztejn B; Veloso VG; Pereira G; Perazzo H
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2187-2195. PubMed ID: 31062880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study.
    Ippolito AM; Milella M; Messina V; Conti F; Cozzolongo R; Morisco F; Brancaccio G; Barone M; Santantonio T; Masetti C; Tundo P; Smedile A; Carretta V; Gatti P; Termite AP; Valvano MR; Bruno G; Fabrizio C; Andreone P; Zappimbulso M; Gaeta GB; Napoli N; Fontanella L; Lauletta G; Cuccorese G; Metrangolo A; Francavilla R; Ciracì E; Rizzo S; Andriulli A
    Dig Liver Dis; 2017 Sep; 49(9):1022-1028. PubMed ID: 28487083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
    Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
    Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
    Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
    World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
    Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
    Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
    Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
    Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
    Roulot D; Thibault V; Laforest C; Fontaine H; Bronowicki JP; Asselah T; Bourlière M; Canva V; Leroy V; Loustaud-Ratti V; Ouzan D; Zoulim F; Schischmanoff O; Rousseau C; Renault A; Petrov-Sanchez V; Diallo A; Bellissant E; Serfaty L;
    Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):302-309. PubMed ID: 29271782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.
    Brzdęk M; Zarębska-Michaluk D; Rzymski P; Lorenc B; Kazek A; Tudrujek-Zdunek M; Janocha-Litwin J; Mazur W; Dybowska D; Berak H; Parfieniuk-Kowerda A; Klapaczyński J; Sitko M; Sobala-Szczygieł B; Piekarska A; Flisiak R
    World J Gastroenterol; 2023 Apr; 29(13):2015-2033. PubMed ID: 37155527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
    Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study.
    Ramadan HK; Badr G; Ramadan NK; Sayed A
    Pathog Dis; 2021 Mar; 79(3):. PubMed ID: 33524139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study.
    Liu CH; Huang YJ; Yang SS; Chang CH; Yang SS; Sun HY; Liu CJ; Liu WC; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Hung CC; Kao JH
    Sci Rep; 2018 Sep; 8(1):13699. PubMed ID: 30209349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Hepatitis C Cirrhotic Patients With Directly Acting Antivirals: A Multicenter Study.
    Elfert AA; Abd-Elsalam S; Abo-Ali L; Eldemerdash T; Abou-Saif S; Elsabagh HM; Ebeid A; Badawi R
    Infect Disord Drug Targets; 2021; 21(5):e270421186971. PubMed ID: 33076813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort.
    Ridruejo E; Piñero F; Mendizabal M; Cheinquer H; Wolff FH; Anders M; Reggiardo V; Ameigeiras B; Palazzo A; Alonso C; Schinoni MI; Zuain MGV; Tanno F; Figueroa S; Santos L; Peralta M; Soza A; Vistarini C; Adrover R; Fernández N; Perez D; Hernández N; Estepo C; Bruno A; Descalzi V; Sixto M; Borzi S; Cocozzella D; Zerega A; de Araujo A; Varón A; Silva M;
    J Med Virol; 2020 Dec; 92(12):3545-3555. PubMed ID: 32749710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.
    Abaalkhail F; Elsiesy H; Elbeshbeshy H; Shawkat M; Yousif S; Ullah W; Alabbad S; Al-Jedai A; Ajlan A; Broering D; Saab S; Al Sebayel M; Al-Hamoudi W
    Transplantation; 2017 Nov; 101(11):2739-2745. PubMed ID: 28795982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials.
    Tacke F; Günther R; Buggisch P; Klinker H; Schober A; John C; Lutz T; Pfeiffer-Vornkahl H; Niederau C; Cornberg M; Sarrazin C; Mauss S
    Liver Int; 2017 Feb; 37(2):205-211. PubMed ID: 27428297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.